Proteomics of osteosarcoma

References

• Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009;152:3-13
   PubMedGoogle Scholar
• Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 2009;28(1-2):247-63
   PubMed Web of Science ®Google Scholar
• Gill J, Ahluwalia MK, Geller D, Gorlick R. New targets and approaches in osteosarcoma. Pharmacol Ther 2012;137(1):89-99
   PubMedGoogle Scholar
• Rainusso N, Wang LL, Yustein JT. The adolescent and young adult with cancer: state of the art – bone tumors. Curr Oncol Rep 2013;15(4):296-307
   PubMed Web of Science ®Google Scholar
• Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006;32(6):423-36
   PubMed Web of Science ®Google Scholar
• Broadhead ML, Clark JC, Myers DE, et al. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011;2011:959248
   PubMedGoogle Scholar
• Dvorak HF. Angiogenesis: update 2005. J Thromb Haemost 2005;3(8):1835-42
   PubMed Web of Science ®Google Scholar
• Clark JC, Thomas DM, Choong PF, Dass CR. RECK – a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 2007;26(3-4):675-83
   PubMedGoogle Scholar
• Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma. Sarcoma 2012;2012:627254
   PubMedGoogle Scholar
• Smida J, Baumhoer D, Rosemann M, et al. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res 2010;16(16):4256-67
   PubMed Web of Science ®Google Scholar
• Shimizu T, Ishikawa T, Sugihara E, et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010;29(42):5687-99
   PubMedGoogle Scholar
• Hattinger CM, Stoico G, Michelacci F, et al. Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. Genes Chromosomes Cancer 2009;48(4):289-309
   PubMedGoogle Scholar
• Ciernik IF, Niemierko A, Harmon DC, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 2011;117(19):4522-30
   PubMed Web of Science ®Google Scholar
• Rikhof B, de Jong S, Suurmeijer AJ, et al. The insulin-like growth factor system and sarcomas. J Pathol 2009;217(4):469-82
   PubMed Web of Science ®Google Scholar
• Nishida T, Nakanishi T, Asano M, et al. Effects of CTGF/Hcs24, a hypertrophic chondrocyte-specific gene product, on the proliferation and differentiation of osteoblastic cells in vitro. J Cell Physiol 2000;184(2):197-206
   PubMed Web of Science ®Google Scholar
• Yang R, Hoang BH, Kubo T, et al. Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 2007;121(5):943-54
   PubMedGoogle Scholar
• Berdiaki A, Datsis GA, Nikitovic D, et al. Parathyroid hormone (PTH) peptides through the regulation of hyaluronan metabolism affect osteosarcoma cell migration. IUBMB Life 2010;62(5):377-86
   PubMedGoogle Scholar
• Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer 2009;115(22):5339-48
   PubMed Web of Science ®Google Scholar
• Arndt CA, Koshkina NV, Inwards CY, et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children’s Oncology Group. Clin Cancer Res 2010;16(15):4024-30
   PubMed Web of Science ®Google Scholar
• Meyers PA, Healey JH, Chou AJ, et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer 2011;117(8):1736-44
   PubMed Web of Science ®Google Scholar
• Goldsby RE, Fan TM, Villaluna D, et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Eur J Cancer 2011;49(10):2384-91
   Google Scholar
• Manetti F, Santucci A, Locatelli GA, et al. Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice. J Med Chem 2007;50(23):5579-88
   PubMed Web of Science ®Google Scholar
• Spreafico A, Schenone S, Serchi T, et al. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. Faseb J 2008;22(5):1560-71
   PubMedGoogle Scholar
• Cotterill SJ, Wright CM, Pearce MS, Craft AW. Stature of young people with malignant bone tumors. Pediatric Blood Cancer 2004;42(1):59-63
   PubMed Web of Science ®Google Scholar
• Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9(4):422-41
   PubMed Web of Science ®Google Scholar
• Calabro T, Mavrogenis AF, Ruggieri P. Osteoblastic osteosarcoma in monostotic Paget’s disease. Musculoskelet Surg 2013;95(1):37-40
   Google Scholar
• Koshy M, Paulino AC, Mai WY, Teh BS. Radiation-induced osteosarcomas in the pediatric population. Int J Radiat Oncol Biol Phys 2005;63(4):1169-74
   PubMedGoogle Scholar
• Bernardini G, Braconi D, Spreafico A, Santucci A. Post-genomics of bone metabolic dysfunctions and neoplasias. Proteomics 2012;12(4-5):708-21
   PubMed Web of Science ®Google Scholar
• Suehara Y, Kubota D, Kikuta K, et al. Discovery of biomarkers for osteosarcoma by proteomics approaches. Sarcoma 2012;2012:425636
   PubMedGoogle Scholar
• Kikuta K, Tochigi N, Saito S, et al. Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics. Proteomics Clin Appl 2010;4(5):560-7
   PubMed Web of Science ®Google Scholar
• Kubota D, Mukaihara K, Yoshida A, et al. Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma. J Proteomics 2013;91:393-404
   PubMed Web of Science ®Google Scholar
• Folio C, Mora MI, Zalacain M, et al. Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets. J Proteome Res 2009;8(8):3882-8
   PubMedGoogle Scholar
• Li Y, Liang Q, Wen YQ, et al. Comparative proteomics analysis of human osteosarcomas and benign tumor of bone. Cancer Genet Cytogenet 2010;198(2):97-106
   PubMedGoogle Scholar
• Flores RJ, Li Y, Yu A, et al. A systems biology approach reveals common metastatic pathways in osteosarcoma. BMC Syst Biol 2012;6:50
   PubMedGoogle Scholar
• Briggs JW, Ren L, Nguyen R, et al. The ezrin metastatic phenotype is associated with the initiation of protein translation. Neoplasia 2012;14(4):297-310
   PubMedGoogle Scholar
• Larance M, Ahmad Y, Kirkwood KJ, et al. Global subcellular characterization of protein degradation using quantitative proteomics. Mol Cell Proteomics 2013;12(3):638-50
   PubMedGoogle Scholar
• Annunen-Rasila J, Ohlmeier S, Tuokko H, et al. Proteome and cytoskeleton responses in osteosarcoma cells with reduced OXPHOS activity. Proteomics 2007;7(13):2189-200
   PubMedGoogle Scholar
• Liontos M, Niforou K, Velimezi G, et al. Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas. Am J Pathol 2009;175(1):376-91
   PubMedGoogle Scholar
• Li Z, Kreutzer M, Mikkat S, et al. Proteomic analysis of the E2F1 response in p53-negative cancer cells: new aspects in the regulation of cell survival and death. Proteomics 2006;6(21):5735-45
   PubMedGoogle Scholar
• Koshkina NV, Khanna C, Mendoza A, et al. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 2007;5(10):991-9
   PubMedGoogle Scholar
• Rao-Bindal K, Zhou Z, Kleinerman ES. MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts. Cell Death Dis 2012;3:e369
   Google Scholar
• Rao-Bindal K, Koshkina NV, Stewart J, Kleinerman ES. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets 2013;13(4):411-22
   PubMed Web of Science ®Google Scholar
• Koshkina NV, Rao-Bindal K, Kleinerman ES. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer 2011;117(15):3457-67
   PubMedGoogle Scholar
• Olkku A, Bodine PV, Linnala-Kankkunen A, Mahonen A. Glucocorticoids induce glutamine synthetase expression in human osteoblastic cells: a novel observation in bone. Bone 2004;34(2):320-9
   PubMed Web of Science ®Google Scholar
• Romanello M, Bivi N, Pines A, et al. Bisphosphonates activate nucleotide receptors signaling and induce the expression of Hsp90 in osteoblast-like cell lines. Bone 2006;39(4):739-53
   PubMedGoogle Scholar
• Thouverey C, Malinowska A, Balcerzak M, et al. Proteomic characterization of biogenesis and functions of matrix vesicles released from mineralizing human osteoblast-like cells. J Proteomics 2011;74(7):1123-34
   PubMedGoogle Scholar
• Li FF, Chen FL, Wang H, et al. Proteomics based detection of differentially expressed proteins in human osteoblasts subjected to mechanical stress. Biochem Cell Biol 2013;91(2):109-15
   PubMedGoogle Scholar
• Xiao Z, Camalier CE, Nagashima K, et al. Analysis of the extracellular matrix vesicle proteome in mineralizing osteoblasts. J Cell Physiol 2007;210(2):325-35
   PubMed Web of Science ®Google Scholar
• Zhou X, Cui Y, Luan J, et al. Label-free quantification proteomics reveals novel calcium binding proteins in matrix vesicles isolated from mineralizing Saos-2 cells. Biosci Trends 2013;7(3):144-51
   PubMedGoogle Scholar
• Zhao M, An M, Wang Q, et al. Quantitative proteomic analysis of human osteoblast-like MG-63 cells in response to bioinert implant material titanium and polyetheretherketone. J Proteomics 2012;75(12):3560-73
   PubMedGoogle Scholar
• Czekanska EM, Stoddart MJ, Richards RG, Hayes JS. In search of an osteoblast cell model for in vitro research. Eur Cell Mater 2012;24:1-17
   PubMed Web of Science ®Google Scholar
• Spreafico A, Frediani B, Capperucci C, et al. A proteomic study on human osteoblastic cells proliferation and differentiation. Proteomics 2006;6(12):3520-32
   PubMedGoogle Scholar
• Liu X, Zeng B, Ma J, Wan C. Comparative proteomic analysis of osteosarcoma cell and human primary cultured osteoblastic cell. Cancer Invest 2009;27(3):345-52
   PubMed Web of Science ®Google Scholar
• Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 2012;52:505-21
   PubMed Web of Science ®Google Scholar
• Sutton CW. The role of targeted chemical proteomics in pharmacology. Br J Pharmacol 2012;166(2):457-75
   PubMed Web of Science ®Google Scholar
• Raida M. Drug target deconvolution by chemical proteomics. Curr Opin Chem Biol 2011;15(4):570-5
   PubMed Web of Science ®Google Scholar
• Lee J, Bogyo M. Target deconvolution techniques in modern phenotypic profiling. Curr Opin Chem Biol 2013;17(1):118-26
   PubMed Web of Science ®Google Scholar
• Russell C, Rahman A, Mohammed AR. Application of genomics, proteomics and metabolomics in drug discovery, development and clinic. Ther Deliv 2013;4(3):395-413
   PubMedGoogle Scholar
• Mikami T, Aoki M, Kimura T. The application of mass spectrometry to proteomics and metabolomics in biomarker discovery and drug development. Curr Mol Pharmacol 2012;5(2):301-16
   PubMedGoogle Scholar
• Muroi M, Kazami S, Noda K, et al. Application of proteomic profiling based on 2D-DIGE for classification of compounds according to the mechanism of action. Chem Biol 2010;17(5):460-70
   PubMedGoogle Scholar
• Kang JH, Park KK, Lee IS, et al. Proteome analysis of responses to ascochlorin in a human osteosarcoma cell line by 2-D gel electrophoresis and MALDI-TOF MS. J Proteome Res 2006;5(10):2620-31
   PubMed Web of Science ®Google Scholar
• Chang YC, Park WH, Min KS, et al. Proteome profiling of U2OS cell line in response to a prenylphenol antibiotic isolated from a phytopathogenic fungus. Biol Pharm Bull 2008;31(9):1696-703
   PubMedGoogle Scholar
• Zhang YK, Zhang XH, Li JM, et al. A proteomic study on a human osteosarcoma cell line Saos-2 treated with diallyl trisulfide. Anticancer Drugs 2009;20(8):702-12
   PubMedGoogle Scholar
• Xie XB, Yin JQ, Wen LL, et al. Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research. PLoS One 2012;7(10):e47375
   Google Scholar
• Li QF, Shi SL, Liu QR, et al. Anticancer effects of ginsenoside Rg1, cinnamic acid, and tanshinone IIA in osteosarcoma MG-63 cells: nuclear matrix downregulation and cytoplasmic trafficking of nucleophosmin. Int J Biochem Cell Biol 2008;40(9):1918-29
   PubMedGoogle Scholar
• Shi SL, Li QF, Liu QR, et al. Nuclear matrix protein, prohibitin, was down-regulated and translocated from nucleus to cytoplasm during the differentiation of osteosarcoma MG-63 cells induced by ginsenoside Rg1, cinnamic acid, and tanshinone IIA (RCT). J Cell Biochem 2009;108(4):926-34
   PubMedGoogle Scholar
• Zhao CH, Li QF, Zhao Y, et al. Changes of nuclear matrix proteins following the differentiation of human osteosarcoma MG-63 cells. Genomics Proteomics Bioinformatics 2006;4(1):10-17
   PubMedGoogle Scholar
• Zhao ZL, Li QF, Zheng YB, et al. The aberrant expressions of nuclear matrix proteins during the apoptosis of human osteosarcoma cells. Anat Rec (Hoboken) 2010;293(5):813-20
   PubMedGoogle Scholar
• Bai Y, Li J, Fang B, et al. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 2012;72(10):2501-11
   PubMed Web of Science ®Google Scholar
• Sau A, Filomeni G, Pezzola S, et al. Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. Mol Biosyst 2012;8(4):994-1006
   PubMedGoogle Scholar
• Gerner C, Gotzmann J, Frohwein U, et al. Proteome analysis of nuclear matrix proteins during apoptotic chromatin condensation. Cell Death Differ 2002;9(6):671-81
   PubMedGoogle Scholar
• Albrethsen J, Knol JC, Jimenez CR. Unravelling the nuclear matrix proteome. J Proteomics 2009;72(1):71-81
   PubMedGoogle Scholar
• Wilson RH, Coverley D. Relationship between DNA replication and the nuclear matrix. Genes Cells 2013;18(1):17-31
   PubMedGoogle Scholar
• Albrethsen J, Knol JC, Piersma SR, et al. Subnuclear proteomics in colorectal cancer: identification of proteins enriched in the nuclear matrix fraction and regulation in adenoma to carcinoma progression. Mol Cell Proteomics 2010;9(5):988-1005
   PubMedGoogle Scholar
• Thompson L, Wang S, Tawfik O, et al. Effect of 25-hydroxyvitamin D3 and 1 alpha,25 dihydroxyvitamin D3 on differentiation and apoptosis of human osteosarcoma cell lines. J Orthop Res 2012;30(5):831-44
   PubMedGoogle Scholar
• Yang QJ, Zhou LY, Mu YQ, et al. All-trans retinoic acid inhibits tumor growth of human osteosarcoma by activating Smad signaling-induced osteogenic differentiation. Int J Oncol 2012;41(1):153-60
   PubMedGoogle Scholar
• Cain JE, McCaw A, Jayasekara WS, et al. Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells. Sarcoma 2013;2013:608964
   PubMedGoogle Scholar
• Yun TK. Panax ginseng – a non-organ-specific cancer preventive? Lancet Oncol 2001;2(1):49-55
   PubMed Web of Science ®Google Scholar
• Bessarabova M, Ishkin A, JeBailey L, et al. Knowledge-based analysis of proteomics data. BMC Bioinformatics 2012;13(Suppl 16):S13
   PubMedGoogle Scholar
• Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol 2012;8(2):e1002375
   PubMed Web of Science ®Google Scholar
• Imielinski M, Cha S, Rejtar T, et al. Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse. Mol Cell Proteomics 2012;11(6):M111.014910
   PubMed Web of Science ®Google Scholar
• Vellaichamy A, Dezso Z, JeBailey L, et al. "Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response. PLoS One 2010;5(6):e10936
   Google Scholar
• Pernemalm M, De Petris L, Branca RM, et al. Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism. J Proteome Res 2013;12(9):3934-43
   PubMed Web of Science ®Google Scholar
• Liu B, Ma W, Jha RK, Gurung K. Cancer stem cells in osteosarcoma: recent progress and perspective. Acta Oncol 2011;50(8):1142-50
   PubMed Web of Science ®Google Scholar
• Dela Cruz FS. Cancer stem cells in pediatric sarcomas. Front Oncol 2013;3:168
   PubMedGoogle Scholar
• Scatena R, Bottoni P, Giardina B. Circulating tumour cells and cancer stem cells: a role for proteomics in defining the interrelationships between function, phenotype and differentiation with potential clinical applications. Biochim Biophys Acta 2013;1835(2):129-43
   PubMed Web of Science ®Google Scholar
• Tirino V, Desiderio V, Paino F, et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. Faseb J 2013;27(1):13-24
   PubMed Web of Science ®Google Scholar
• Gibbs CP, Kukekov VG, Reith JD, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005;7(11):967-76
   PubMed Web of Science ®Google Scholar
• Adhikari AS, Agarwal N, Wood BM, et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 2010;70(11):4602-12
   PubMed Web of Science ®Google Scholar
• Levings PP, McGarry SV, Currie TP, et al. Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 2009;69(14):5648-55
   PubMed Web of Science ®Google Scholar
• Fujii H, Honoki K, Tsujiuchi T, et al. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol 2009;34(5):1381-6
   PubMed Web of Science ®Google Scholar
• Wang L, Park P, Lin CY. Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol Ther 2009;8(6):543-52
   PubMed Web of Science ®Google Scholar
• Zhou S, Li F, Xiao J, et al. Isolation and identification of cancer stem cells from human osteosarcoma by serum-free three-dimensional culture combined with anticancer drugs. J Huazhong Univ Sci Technolog Med Sci 2010;30(1):81-4
   PubMedGoogle Scholar
• Tirino V, Desiderio V, d’Aquino R, et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 2008;3(10):e3469
   PubMed Web of Science ®Google Scholar
• Di Fiore R, Santulli A, Ferrante RD, et al. Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol 2009;219(2):301-13
   PubMedGoogle Scholar
• Song B, Wang Y, Titmus MA, et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010;9:96
   PubMed Web of Science ®Google Scholar
• Song B, Wang Y, Xi Y, et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009;28(46):4065-74
   PubMed Web of Science ®Google Scholar
• Makridakis M, Roubelakis MG, Bitsika V, et al. Analysis of secreted proteins for the study of bladder cancer cell aggressiveness. J Proteome Res 2013;9(6):3243-59
   Google Scholar
• Saini V, Hose CD, Monks A, et al. Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS One 2012;7(8):e41401
   PubMed Web of Science ®Google Scholar
• Arai K, Sakamoto R, Kubota D, Kondo T. Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system. Proteomics 2013;13(15):2351-60
   PubMed Web of Science ®Google Scholar
• Gemei M, Corbo C, D’Alessio F, et al. Surface proteomic analysis of differentiated versus stem-like osteosarcoma human cells. Proteomics 2013;13(22):3293-7
   PubMedGoogle Scholar
• Godugu C, Patel AR, Desai U, et al. AlgiMatrix based 3D cell culture system as an in-vitro tumor model for anticancer studies. PLoS One 2013;8(1):e53708
   PubMed Web of Science ®Google Scholar
• Di Fiore R, Fanale D, Drago-Ferrante R, et al. Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: a possible model for studying osteosarcoma origin and stemness. J Cell Physiol 2013;228(6):1189-201
   PubMedGoogle Scholar